Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eicosapentaenoic acid + docosapentaenoic acid
- Development stage
- Phase 2
- Lead developer
- Matinas BioPharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of omega-3 polyunsaturated fatty acids (PUFAs) consisting of eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA). This specific formulation was evaluated by the National Institute on Drug Abuse (NIDA) in Phase 2 clinical trials for the treatment of cocaine and alcohol dependence. The rationale for its use is based on the observation that substance-dependent individuals often exhibit depleted levels of PUFAs, which are critical for maintaining neuronal membrane integrity and modulating neurotransmitter systems involved in reward, aggression, and mood regulation. By supplementing these fatty acids, the treatment aims to reduce relapse rates, decrease aggressive behavior, and alleviate depressive symptoms associated with addiction recovery.
- Other names
- Pro-eicosapentaenoic acid (EPA)Pro-docosapentaenoic acid (DPA)n-3 polyunsaturated fatty acidsn3 polyunsaturated fatty acidsn 3 polyunsaturated fatty acidsn-3 PUFAsn3 PUFAsn 3 PUFAsOmega-3 fatty acidsOmega3 fatty acidsOmega 3 fatty acids
02
Targets
FFAR4 (Free fatty acid receptor 4)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on eicosapentaenoic acid + docosapentaenoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eicosapentaenoic acid + docosapentaenoic acid.